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Weighted Pathway Genetic Load Analysis
of Hyperbilirubinemic Infants Indicates a
Potential Genetic Component for
Susceptibility to Bilirubin Neurotoxicity
Sean M. Riordan1,2,3, J.B. Le Pichon1,2,3, John D. Cowden1,2,
Monica VillaGuillen4, Steven M. Shapiro1,2,3 , Laurence
Thielemans5, Dina Villanueva Garcia4, Jesus AguirreHernandez4
smriordan@cmh.edu

Background:

Severe kernicterus spectrum disorder (KSD) is described as motor and
auditory deficits resulting from brain damage caused by
hyperbilirubinemia (HB). Interestingly, the severity of HB does not always
sufficiently predict the severity of injury. Numerous genetic mutations
result in severe HB in neonates, but the role of genetics to bilirubin
neurotoxicity remains unclear. The lack of a strong monogenetic link to
susceptibility suggests bilirubin-induced brain damage may be due to
impaired bilirubin response pathways

Objective:

Identification of critical pathway
genetic load scores related to
susceptibility
to
bilirubin
neurotoxicity in neonates is
enhanced by weighting genetic
variants using CADD scoring.

Figure 2: Distribution of patients by
KSD severity and peak TB. Dashed
line at 25 indicates moderate vs.
severe TB classification

Figure 3:mPGL and mPGL+ scores do not correlate with TB levels

The objective of this work is to use a modified pathway genetic load
(mPGL) score method to perform a targeted genetic analysis of whole
exome data from patients with various degrees of neonatal HB, with an
ultimate goal of developing a neonatal screen to susceptibility to bilirubin
neurotoxicity

Study Design:

• Retrospective Cohort Study
• Inclusion Criteria
• History of severe HB (total bilirubin (TB) > 15 mg/dL in the first
month of life
• > 36 weeks gestational age
• Exclusion Criteria (at time of HB exposure)
• Active infection
• Hypoxic ischemic encephalopathy
• Other metabolic developmental abnormalities
• Study sites (Cases / Controls)
• USA – Children’s Mercy Hospital – (8/16)
• Mexico – Hospital Infantil de Mexico Federico Gomez (7/23)
• Thailand – Shoklo Malaria Research Unit (13/0)

Sequencing and Variant Calling:

Whole Exome Sequencing (WES) was performed on DNA samples at
either CMH or HIMFG via Illumina Next Generation Sequencing. Variant
data was validated via the CMH bioinformatics pipeline. Variants were
called using Variant Integration and Knowledge Interpretation in
Genomes (VIKING) software developed at Children’s Mercy Hospital [1].

mPGL and mPGL+ scoring:

Known and predicted pathogenic variants were identified in two gene
lists, counted, and weighted by zygosity to produce modified Pathway
Genetic Load (mPGL) scores for each individual [2]. Gene lists for variant
filtering were curated based on known genetic contributors to jaundice
(Tier 1) and bilirubin responders in human and mouse neuronal and glial
cell culture (Tier 2). mPGL+ scores were created by weighting each
variant identified using the Combined Annotation Dependent Depletion
(CADD) scoring system (https://cadd.gs.washington.edu) [3].
For dichotomous analysis samples were separated into four groups
(Figure 1) where mild jaundice was considered a peak bilirubin of 15 – 25
mg/dL and severe jaundice was >25 mg/dL. KSD severity was
determined by clinical evaluation. Familial control samples were also
collected for future inheritance analysis. Average mPGL and mPGL+
scores for each tier were analyzed via one-way ANOVA with Tukey’s
multiple comparison post-test (p<0.05). For continuous analysis mPGL
and mPGL+ scores were plotted against KSD severity and analyzed by
linear regression analysis.

Figure 1: Comparison of average mPGL (unweighted) and
mPGL+ (CADD weighted) scores in groups separated by
severity of bilirubin exposure and severity of kernicterus. Tier 1
genes are classically identified as causing hyperbilirubinemia.
Tier 2 genes are those identified as bilirubin responders in in
vitro neuronal and glial studies from the literature.
Symbol
Description
B + KSD Bilirubin ≤ 25 mg/dl and Mild Kernicterus
B + KSD Bilirubin ≥ 25 mg/dl and Mild Kernicterus
B + KSD Bilirubin ≥ 25 mg/dl and Severe Kernicterus
B + KSD Bilirubin ≤ 25 mg/dl and Severe Kernicterus

Figure 4 :mPGL and mPGL+ scores do not correlate with Severity of KSD
in Tier 1 or Tier 2 gene lists

Next Steps:

• Proceed to a prospective study in an effort to reduce
compounding clinical variables and include free bilirubin
measurements for data analysis.
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Results and Conclusions
•
•

Only 1 group comparison in the mPGL+ Tier 1 analysis proved to be
statistically significant, High Bilirubin & Mild KSD vs. Low Bilirubin &
Severe KSD.
We hypothesized that increased mPGL scores would correlate with
increased susceptibility to bilirubin neurotoxicity but these results show
the oppositte effect and indicate a need for increased study and
thoughtful evaluation of the mPGL score and the gene lists used here.
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